Abacavir induces loading of novel self-peptides into HLA-B*57: 01 an autoimmune model for HLA-associated drug hypersensitivity

No abstract is available for this paper.

• Publication year

  2012

• Venue

  AIDS (London)

• Publication date

  2012-07-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e328355fe8fPMID 22617051PMCID PMC4155923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.

  2012cited by this paper
• Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.

  2012cited by this paper
• Delayed drug hypersensitivity: models of T-cell stimulation.

  2011cited by this paper
• HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

  2011cited by this paper
• HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients

  2010cited by this paper
• HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

  2009cited by this paper
• The Immune Epitope Database 2.0

  2009cited by this paper
• Harvesting Candidate Genes Responsible for Serious Adverse Drug Reactions from a Chemical-Protein Interactome

  2009cited by this paper
• Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

  2008cited by this paper
• The quality control of MHC class I peptide loading.

  2008influential reference
• HLA-B*5701 Screening for Hypersensitivity to Abacavir

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

  2007cited by this paper
• Medical Genetics: A Marker for Stevens-Johnson SyndromeChung W-H, Hung S-I, Hong H-S, et al (Chang Gung Mem Hosp, Taipei, Taiwan; Inst of Biomedical Sciences, Taipei, Taiwan) Nature 428:486, 2004§

  2006cited by this paper
• HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

  2005cited by this paper
• Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery.

  2005cited by this paper
• Erratum: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol (Proceedings of the National Academy of Sciences of the United States of America (March 15, 2005) 102, 11 (4134-4139))

  2005cited by this paper
• Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization.

  2004cited by this paper
• The danger hypothesis applied to idiosyncratic drug reactions.

  2003cited by this paper
• The danger hypothesis applied to idiosyncratic drug reactions

  2003cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept

  2002cited by this paper
• The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.

  2002cited by this paper
• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  2002cited by this paper
• SYFPEITHI: database for MHC ligands and peptide motifs

  1999cited by this paper
• Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity.

  1997cited by this paper
• Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501

  1997cited by this paper

• Relevance of Reactive Metabolites and Covalent Binding to Drug Candidate Selection.

  2026cites this paper
• HLA‐A*02:01 Presents Penicillin‐Modified Cysteinylated Peptides for T Cell Recognition

  2025cites this paper
• Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice.

  2025cites this paper
• Differential Alloreactivity: Lessons Learned From a Singular HLA Locus

  2025cites this paper
• Genetic and Genomic Approaches to the Study of Drug‐Induced Liver Injury

  2024cites this paper
• Selective HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific Human T-Cells

  2024cites this paper
• Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis

  2024cites this paper
• Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes

  2024cites this paper
• Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology.

  2024cites this paper
• Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

  2023cites this paper
• Immunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directions

  2023cites this paper
• Novel insights into molecular and cellular aspects of delayed drug hypersensitivity reactions

  2023cites this paper
• Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01

  2023cites this paper
• Activation of human CD8+ T-cells with nitroso dapsone-modified HLA-B*13:01-binding peptides

  2023cites this paper
• Recent Advances in Molecular Mechanisms of Nucleoside Antivirals

  2023cites this paper
• Tools for Etiologic Diagnosis of Drug-Induced Allergic Conditions

  2023cites this paper
• The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors

  2023cites this paper
• What’s been Hapten-ing over the last 88 years?

  2023cites this paper
• Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation

  2023cites this paper
• Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics

  2022cites this paper
• Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance

  2022cites this paper
• Editorial: The Immunology of Adverse Drug Reactions

  2022cites this paper
• HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity.

  2022cites this paper
• Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects

  2022cites this paper
• Biochemical mechanisms of drug toxicity

  2022cites this paper
• Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.

  2022cites this paper
• Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele

  2022cites this paper
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication

  2022cites this paper
• In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation

  2022cites this paper
• Genetics and Molecular Biology

  2022cites this paper
• MHC Class I Immunopeptidome: Past, Present, and Future

  2022cites this paper
• Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors

  2022cites this paper
• Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions

  2022cites this paper
• Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides

  2021cites this paper
• Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges

  2021cites this paper
• HLA Class II-restricted CD8+ T cells contribute to the promiscuous immune response in dapsone hypersensitive patients.

  2021cites this paper
• SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage

  2021influential citation
• Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01

  2021cites this paper
• The relationship between COVID‐19 and HLA in kidney transplant recipients, an evaluation of predictive and prognostic factors

  2021cites this paper
• HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema

  2021cites this paper
• Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition

  2021cites this paper
• The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions

  2021cites this paper
• HIV-1 and human genetic variation

  2021cites this paper
• The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions

  2021cites this paper
• Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire

  2021cites this paper
• The Impact of the ‘Mis-Peptidome’ on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response

  2020cites this paper
• Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)

  2020cites this paper
• Pharmacogenomics of Drug-Induced Liver Injury

  2020cites this paper
• Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation.

  2020cites this paper
• Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA‐B*57:01 binding and T‐cell activation

  2020cites this paper
• Shedding light on drug-induced liver injury: activation of T-cells from drug naive human donors with tolvaptan and a hydroxybutyric acid metabolite.

  2020cites this paper
• Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

  2020cites this paper
• How Mechanism Knowledge Can Help to Management of Drug Hypersensitivity

  2020cites this paper
• Discovery of novel HLA-B*57:01 restricted T-cell antigens through genome-wide screening of Epstein-Barr virus

  2020influential citation
• Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives

  2020cites this paper
• Definition of the Chemical and Immunological Signals Involved in Drug-induced Liver Injury.

  2020cites this paper
• T-cell activation by low molecular weight drugs and factors that influence susceptibility to drug hypersensitivity.

  2020cites this paper
• Noninfectious Environmental Agents and Autoimmunity

  2020cites this paper
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

  2020cites this paper
• The Low Risks and High Rewards of Penicillin Allergy Delabeling: An Algorithm to Expedite the Evaluation.

  2019cites this paper
• Reviewing the mechanistic evidence assessors E-Synthesis and EBM+: A case study of amoxicillin and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

  2019cites this paper
• HLA‐associated antiepileptic drug‐induced cutaneous adverse reactions

  2019cites this paper
• Allergic reactions to small-molecule drugs: Will we move from reaction to prediction?

  2019cites this paper
• Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

  2019cites this paper
• Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

  2019cites this paper
• Immune pathomechanism and classification of drug hypersensitivity

  2019cites this paper
• Comparison of abacavir‐specific effector and proliferating functions of CD8 T cells in abacavir‐treated HIV‐1 patients

  2019cites this paper
• Detection and phenotypic characterization of drug (metabolite)-specific t-cells from patients with drug-induced skin and liver injury and healthy donors

  2019cites this paper
• Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles

  2019cites this paper
• Immunogenicity Risks for Naturally Derived Complex Drugs

  2019cites this paper
• Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing

  2019cites this paper
• The Science and Regulations of Naturally Derived Complex Drugs

  2019cites this paper
• HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

  2019cites this paper
• Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics

  2019cites this paper
• Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions

  2019cites this paper
• MHC Molecules, T cell Receptors, Natural Killer Cell Receptors, and Viral Immunoevasins-Key Elements of Adaptive and Innate Immunity.

  2019cites this paper
• Drug-induced injury due to flucloxacillin: relevance of multiple HLA alleles

  2018cites this paper
• Allergies et médicaments : mécanismes de présentation de l’antigène au système immunitaire adaptatif

  2018cites this paper
• Precision medicine for HIV: where are we?

  2018cites this paper
• Generation and characterization of dapsone- and nitroso-dapsone-specific T-cells: an insight into the molecular pathomechanism of dapsone hypersensitivity syndrome.

  2018cites this paper
• Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions

  2018cites this paper
• Immunopeptidomics Special Issue

  2018cites this paper
• Current aspects in sepsis approach. Turning things around

  2018cites this paper
• Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02

  2018cites this paper
• Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions

  2018cites this paper
• HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity

  2018cites this paper
• Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.

  2018cites this paper
• PharmGKB: A worldwide resource for pharmacogenomic information

  2018cites this paper
• Development of a non-mammalian, pre-clinical screening tool for the predictive analysis of drug toxicity

  2018cites this paper
• Active suppression rather than ignorance: tolerance to abacavir‐induced HLA‐B*57:01 peptide repertoire alteration

  2018cites this paper
• A transgenic mouse model for HLA‐B*57:01‐linked abacavir drug tolerance and reactivity

  2018cites this paper
• Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention

  2018cites this paper
• A case of acute fever, rash and vomiting

  2018cites this paper
• The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash

  2018cites this paper
• Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice

  2018cites this paper
• In-silico approach for drug induced liver injury prediction: Recent advances.

  2018cites this paper
• The dawn of precision medicine in HIV: state of the art of pharmacotherapy

  2018cites this paper